March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Ocular Disease Associated with Hematopoietic Stem Cell Transplantation
Author Affiliations & Notes
  • Travis C. Rumery
    Ophthalmology, Kellogg Eye Ctr-Univ of Michigan, Ann Arbor, Michigan
  • Shahzad Mian
    Ophthalmology, Kellogg Eye Ctr-Univ of Michigan, Ann Arbor, Michigan
  • Joshua Stein
    Ophthalmology, Kellogg Eye Ctr-Univ of Michigan, Ann Arbor, Michigan
  • Footnotes
    Commercial Relationships  Travis C. Rumery, None; Shahzad Mian, Investigator Grant from Bausch and Lomb (F); Joshua Stein, Blue Cross Blue Shield of Michigan Foundation; Research to Prevent Blindness; National Eye Institute K23 Mentored Clinician Scientist Award (F)
  • Footnotes
    Support  National Eye Institute K23 Mentored Clinician Scientist Award (1K23EY019511-01); Blue Cross and Blue Shield of Michigan Foundation; Research to Prevent Blindness; Alliance for Vision
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 570. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Travis C. Rumery, Shahzad Mian, Joshua Stein; Ocular Disease Associated with Hematopoietic Stem Cell Transplantation. Invest. Ophthalmol. Vis. Sci. 2012;53(14):570.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the epidemiology and risk factors associated with ocular disease after hematopoietic stem cell transplantation (HSCT).

Methods: : Claims data from a large, United States managed care network were retrospectively analyzed. ICD-9-CM Billing codes were used to identify patients who underwent autologous or allogeneic HSCT from 2001 to 2009 and to assess the new onset of ocular complications associated with HSCT and whether they vary based on the type of HSCT (autologous vs allogeneic). Comparisons of the proportion of enrollees who experienced GVHD, development of severe dry eyes (DES), conjunctivitis, keratitis, and cataract were performed at 6 weeks, 3 months, 6 months, 1 year, 2 years, 3 years, 4 years, and 5 years following HSCT.

Results: : There were a total of 484 patients who underwent allogeneic HSCT and 94 patients who underwent autologous HSCT during their time in the plan. Among those who underwent allogeneic HSCT, the proportion who developed GVHD was 3.52% at 3 months, 2.96% at 1 year and 5.0% at 5 years. No patients in the autologous HSCT group developed GVHD. The proportion of patients who developed severe DES was higher in the allogeneic group when compared to the autologous group up to 2 years (p=0.0365). The proportion of patients who developed conjunctivitis was similar in both groups at all time points (p>0.2). The proportion of patients who developed keratitis was higher up to 3 months in the allogeneic HSCT group when compared to the autologous HSCT group (p=0.037). A new diagnosis of cataract was more frequent in the allogeneic BMT group up to 6 months after HSCT (p=0.0323).

Conclusions: : Ocular disease is common after HSCT. Physicians should be aware of the overall disease burden of ocular GVHD to facilitate appropriate eye care for patients undergoing HSCT in order to minimize ocular morbidity.

Keywords: clinical (human) or epidemiologic studies: outcomes/complications • clinical (human) or epidemiologic studies: prevalence/incidence • cornea: tears/tear film/dry eye 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×